V
Visterra
Developing transformative biologics for immune-mediated and hard-to-treat diseases
About Visterra
Visterra is a biologics research and early-stage clinical development company focused on creating therapies for patients suffering from immune-mediated and other challenging diseases. The company operates in the biotechnology sector, primarily serving patients with conditions in nephrology, rheumatology, transplant immunology, and neurology. Visterra's business model revolves around the research, development, and early clinical testing of biologic drugs, leveraging cutting-edge technologies to engineer novel therapies. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its developed therapies. As part of the Otsuka family of companies, Visterra benefits from the support and stability of a long-established global entity while maintaining the agility and innovation of a smaller organization. The company also offers a Co-Op program to provide students with valuable industry experience and exposure to innovative research and technologies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Cambridge, United States
- Employees
- 133
- Open positions
- 4
- Dealroom signal
- 76.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2018 | $430M | — | Otsuka Pharmaceutical | — |
| SERIES COther financing | Oct 2017 | $47M | $187M | Polaris Partners · Vertex Holdings · Cycad Group · Omega Funds | ↗ |
Growth signals
Latest recorded traffic for Visterra is 5K monthly website visits, down 9.1% over the last three months. Visterra's team grew 47.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later8 investors entered at this stage
Lux Capital
Polaris Partners
Flagship Pioneering
Vertex Holdings- CGCycad Group
Omega Funds
Alexandria Venture Investments
Bill & Melinda Gates Foundation
Other known investors2 additional known investors
Massachusetts Institute of Technology
Otsuka Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Visterra on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Visterra’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.